InnoCare Pharma’s Post

DEAL HIGHLIGHT: Instil Bio and ImmuneOnco Partnership Instil Bio gains rights to develop and commercialize two clinical-stage assets (IMM2510 and IMM27) worldwide, except in Greater China, allowing them to expand their oncology pipeline. KEY TAKEAWAYS: FINANCIAL TERMS:  The deal is valued at $2.12 billion, including a $10 million upfront payment, $40 million in near-term milestones and up to $2.07 billion in development, regulatory, and commercial milestones, plus tiered royalties. EXPANSION OF INSTIL BIO's PIPELINE: This partnership repositions Instil Bio with a stronger clinical-stage portfolio, helping to fill its pipeline with two promising clinical stage assets that could accelerate its growth in the oncology space. CROSS-BORDER DEAL: ImmuneOnco retains rights within Greater China (mainland China, Taiwan, Hong Kong, and Macau), facilitating a cross-border exchange of innovative therapies, aiming for a broader global impact.

🤝 𝐌𝐨𝐟𝐟𝐢𝐭𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐞𝐧𝐭𝐞𝐫 & 𝐉𝐚𝐩𝐚𝐧'𝐬 𝐂𝐑𝐎 𝐉𝐨𝐢𝐧 𝐅𝐨𝐫𝐜𝐞𝐬 𝐭𝐨 𝐅𝐢𝐠𝐡𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐖𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞!🌍💊 𝗜𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟰, Tampa’s Moffitt Cancer Center is forging an international partnership with Japan’s largest #CRO, CMIC, to improve the ability of both #organizations to run global #cancertrials. Under the deal, Moffitt will serve as the go-to U.S. site for CMIC’s trials, while CMIC will help manage Moffitt’s trials in Japan and across the Asia-Pacific region. The goal of the partnership is to accelerate cross-border clinical trials for new therapies and #increase the diversity of trial participants, according to the release. According to the company's press announcement, CMIC is the first and biggest CRO in Japan, operating in 12 nations including #Australia, #China, #SouthKorea, and #Taiwan. Around this time last year, the company entered into another U.S. agreement when it agreed to work with Rutgers University to construct a pharmaceutical #production plant in New Jersey. 𝙇𝙤𝙤𝙠 𝙖𝙩 𝙤𝙪𝙧 𝘾𝙤𝙧𝙧𝙚𝙡𝙖𝙩𝙚𝙙 𝙍𝙚𝙥𝙤𝙧𝙩 👉 https://lnkd.in/dikP5H69 #ClinicalTrials #CROPartnership #GlobalHealth #CancerBreakthroughs #InnovativeMedicine

Hey, what's the best-selling pharmaceutical product in the world? Right. Now, what happens when a small Biotech shows that they can generate better results in the same disease state (maybe states)? https://lnkd.in/gGadFPvM My first reaction was that there's going to be a kerfuffle over these results being in China only. Not just from a data quality perspective, wondering about differential responses from other groups, but also because we have this huge issue with Chinese companies all of a sudden. If the United States blocks out Chinese companies like WuXi over IP and data integrity, what's to keep China from responding in kind? I can also imagine people asking why Summit chose to perform their trials in China only. Welp, it turns out it's not that big of a deal. The clinical data were generated by Akeso, Summit's partner in China. But it turns out that Summit bought the rights to ivonescimab outright back in 2022, and they bought them from.....Akeso. So it makes sense that those data are coming from China, because that's where they started. Check the Endpoints article for details on how Duggan sold Pharmacyclics, then buying most of Summit. Summit's lead candidate failed PhIII, so they pivoted to buy ivonescimab from Akeso. That's a huge swing in fortune, in every sense of the phrase. It also goes to show us (again) that there's more than one way to build a pipeline. #keytruda #summit #china #pharma #clinicaltrials

𝗙𝗼𝗴𝗣𝗵𝗮𝗿𝗺𝗮 𝗯𝗮𝗴𝘀 $𝟭𝟰𝟱𝗠, 𝗮𝗱𝗱𝘀 𝗔𝗹𝗲𝘅𝗶𝘀 𝗕𝗼𝗿𝗶𝘀𝘆 𝘁𝗼 𝘁𝗵𝗲 𝗯𝗼𝗮𝗿𝗱 FogPharma, a biotech from Harvard researcher Greg Verdine that is led by former Johnson & Johnson R&D leader Mathai Mammen, M.D., Ph.D., said it has raised $145 million in a Series E financing. The nine-figure round, biotech’s 13th of 2024, was led by Nextech Invest and included participation from Alex Gorsky, Mammen’s former boss at J&J. The Boston-area biotech is one of a few drug developers to raise that many private rounds before a move to the public markets. The biotech last disclosed a $178 million Series D in November 2022. “I do want to eventually be a public company, but I want to be a really good, solid, robust public company that has multiple milestones that can take hits on failures, which are going to be expected in this industry from time to time, so I don’t want to go out as a fragile company,” Mathai Mammen, M.D., Ph.D. said in an interview with Endpoints News on Jan. 12. “Even if the environment were very conducive to being public right now, I still wouldn’t want to be a public company right now. We’re not in a position to do that,” Mammen continued in the January interview, which came before six biotechs would make the transition to the public markets, including other oncology drugmakers like CG Oncology and ArriVent Biopharma. Nextech designated industry entrepreneur and Curie.Bio co-founder Alexis Borisy to FogPharma’s board, the drug developer also said Friday morning. FogPharma said the funds will go toward the clinical-stage candidate FOG-001, one of the few beta catenin inhibitors to make it into human studies. The candidate is in a Phase I/II in solid tumors. Mammen told Endpoints in January that there were less than a dozen patients in the trial, noting it was still “super-early days.” https://lnkd.in/gKnTEbdt

𝗕𝘂𝘀𝘆 𝘄𝗲𝗲𝗸𝗲𝗻𝗱 𝗳𝗼𝗿 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 Here’s 3 key developments 👇 1. 𝗦𝗺𝗮𝗿𝘁𝗖𝗲𝗹𝗹𝗮 𝗛𝗼𝗹𝗱𝗶𝗻𝗴 𝗔𝗕 𝗵𝗮𝘀 𝗿𝗮𝗶𝘀𝗲𝗱 𝗘𝗨𝗥 𝟱𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 Funds are to accelerate its growth and commercialisation of the Extroducer and its cell and mRNA operations. The funding round was backed by existing investors such as Fjärde AP-fonden, AMF Pension, and SEB-Stiftelsen, along with new strategic investor AstraZeneca, which committed to about 1/2 of the share issue. 2. 𝗜𝗻𝗻𝗼𝘃𝗲𝗻𝘁 𝗧𝗿𝗮𝗻𝘀𝗳𝗲𝗿𝘀 𝗖𝗔𝗥 𝗧-𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗦𝘁𝗮𝗸𝗲 𝘁𝗼 𝗜𝗔𝗦𝗢 𝗕𝗶𝗼 👉 Innovent Biologics has transferred its license for Fucaso (equecabtagene autoleucel), a CAR T-cell therapy approved in China for relapsed/refractory multiple myeloma, to IASO Bio In exchange, Innovent will receive an 18% equity stake in IASO Bio, which now holds global commercial rights to Fucaso. 3. 𝗖𝗮𝗿𝘁𝗲𝘀𝗶𝗮𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗦𝗲𝗰𝘂𝗿𝗲𝘀 𝟭𝟯𝟬 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝗳𝗼𝗿 𝗺𝗥𝗡𝗔 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 👉 Cartesian Therapeutics raised $130 million through PIPE financing to support its pipeline and operations. The company also dosed the first patient in its Phase 2 trial of Descartes-08, an mRNA CAR-T therapy for systemic lupus erythematosus, designed to avoid preconditioning chemotherapy and reduce genomic integration risks. #celltherapy #stemcell #biotech #CGTweekly

Join us in San Diego for #RNALeaders Sept 4, 5.  We are updating partners on our latest IV-formulated RNA program data. BIORCHESTRA Co., Ltd.'s #RNAi update covers: ✨ In-vivo progress on our neurodegenerative diseases franchise and proprietary IV-formulated RNAi research in #Alzheimer's and #Parkinson's ✨ Status of our #ALS program FDA IND pathway  ✨ Licensing negotiations for #MAPT, #SNCA, #INHBE/ #MAFLD, and #Glaucoma ✨ Our bridge round syndicate and #NYSE pathway To those requesting one-on-ones though LinkedIn, please reach us at davidoxley@biorchestra.com Novo Nordisk, SV Health Investors, PJT Partners, Perella Weinberg, William Blair Investment Banking, Jefferies, Leerink Partners, Nomura Securities International, Inc., Cain Brothers, UBS, Oppenheimer & Co. Inc., Wells Fargo Corporate & Investment Banking, Guggenheim Partners, Outcome Capital, Eric J. Dimise, PhD, Michael Bardi, Michael Zhang, Veet Misra, Cantor Fitzgerald, Noël Brown, Samuel Siu, CPA, RBC Capital Markets, John C. Reed, Novo Holdings, Lilly Asia Ventures 礼来亚洲基金, Sumitomo Mitsui Banking Corporation – SMBC Group, #pfizercolleague, Centerview Partners, Morgan Stanley Investment Management, Bank of America, Mallinckrodt Pharmaceuticals, Grünenthal Group, Evercore, New York Stock Exchange https://lnkd.in/gaWRkNDU The Janssen Pharmaceutical Companies of Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., ONO PHARMA USA, ONO PHARMACEUTICAL CO., LTD., Sanofi, Novartis Gene Therapies

Check our principal Jiamin Zhuo's commentary in the latest issue of "Asian Biotechies Walk Into A Bar" #newsletter.

I'm pleased to announce the addition of Jeeshan Chowdhury, MD, Ph.D., Chief Executive Officer & Co-Founder, Journey Colab to the agenda for the 4th Annual Psychedelic Therapeutics Conference, taking place in Boston on May 23-24, 2024. He will be discussing the issue of fundraising for psychedelic drug programs. In the ever-evolving landscape of drug development, securing later-stage funding remains a critical bottleneck, especially in the burgeoning field of psychedelic medicine. One of the key challenges currently facing drug development companies is navigating the complex path from research to commercialization. This session aims to introduce a groundbreaking approach to address this challenge. This session will be of particular interest to drug developers grappling with commercialization challenges. This approach is uniquely positioned to not only advance the clinical science but also to build a strategy for commercialization, thereby addressing the most pressing issue in the psychedelic industry today. Learn more about this event by visiting https://lnkd.in/eM5iiPn. #psychedelics #psychedelicresearch #psychedelictherapy #boston

🚨 The Most-Read M&A Deal Today: Goldman Sachs Leads Advisory on $1.8bn Biogen Biotech Acquisition - Deal Summary Krugman Insights offers Reliable and Comprehensive Insights across M&A, Investment Banking, Private Equity, and Asset Management. 🔎 Financial Advisors on the Deal: Goldman Sachs, Bank of America 🔎 Legal Advisors on the Deal: Goodwin, Covington & Burling LLP 💡 Biogen has agreed to acquire HI-Bio (Human Immunology Biosciences) for $1.8 billion, including an upfront payment of $1.15 billion and up to $650 million in milestone payments. This acquisition will bolster Biogen’s late-stage pipeline with HI-Bio’s lead asset, felzartamab, an anti-CD38 monoclonal antibody showing promise in treating rare immune-mediated diseases like primary membranous nephropathy (PMN) and antibody-mediated rejection (AMR) in kidney transplants. Biogen plans to leverage its immunology and rare disease expertise to advance HI-Bio’s pipeline. The transaction, subject to regulatory approvals, is expected to close in Q3 2024. ✅ FULL ARTICLE HERE: https://lnkd.in/e3A3mWz8 ✅ TRY 30 DAYS FREE: https://lnkd.in/eBHYx37M #GoldmanSachs #BofA #Biogen #HIBio #MergersAndAcquisitions #InvestmentBanking #CorporateFinance #Biotechnology #StrategicPartnership #FinancialAdvisory

𝐔𝐧𝐧𝐚𝐭𝐮𝐫𝐚𝐥 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬, 𝐈𝐧𝐜. 𝐄𝐧𝐭𝐞𝐫𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐌𝐞𝐫𝐜𝐤 Unnatural Products, Inc. (UNP) Unnatural Products Inc. collaborates with Merck (known as MSD outside the United States and Canada) MSD to leverage UNP's AI-infused chemistry for developing macrocyclic candidates against a challenging oncology target. Cameron Pye Cameron Pye, CEO of UNP, underscores the partnership's importance in tackling complex oncology issues and praises Merck's commitment to cutting-edge science. This collaboration signifies a leap forward in the pursuit of innovative oncology solutions, blending AI prowess with medicinal chemistry. UNP will receive an upfront payment and is eligible for milestone payments of up to $220 million tied to candidate product development and commercialization. #BiotechInnovation #OncologyResearch #AIinDrugDiscovery #Collaboration #ScienceAdvancements